[1]
Karaman, O. et al. 2025. CD19 Chimeric Antigen Receptor (CAR) modified cytokine killer cells compared to classical CD19 CAR-T: advantages and disadvantages. South East European Journal of Immunology. 8, CITIM (Mar. 2025), 062. DOI:https://doi.org/10.3889/seejim.2025.6123.